And these findings corroborates the discovery by Wang et al., demonstrating that ESRRG potentiates responsiveness to anti-PD-1 therapy in esophageal squamous cell carcinoma (24). This evidence concerns the gene ESRRG and esophageal squamous cell carcinoma.